Rhythm Pharma Shares Drop as Obesity Drug Fails Late-Stage Clinical Trial

Event Summary

Rhythm Pharmaceuticals' experimental drug for genetic obesity failed to meet the primary goal of its late-stage clinical trial, leading to a sharp drop in its shares. Meanwhile, competing drugs have shown positive weight loss results, including Wegovy® HD, which received FDA approval. Novo Nordisk also cut prices on obesity drugs in India in response to the influx of cheaper generic medications in the market.